FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus

FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus

Abstract Background The study aimed to investigate an association of increased liver fibrosis with acute myocardial infarction (AMI), and to investigate the mediating effect of serum follistatin-like protein 3 (FSTL3) on the association in patients with type 2 diabetes mellitus (T2DM). Method A tota...

Full description

Bibliographic Details
Main Authors:	Wenfei Duan, Ruixiao Shi, Fang Yang, Zhoujunhao Zhou, Lihong Wang, Zhe Huang, Shufei Zang
Format:	Article
Language:	English
Published:	BMC 2023-10-01
Series:	Cardiovascular Diabetology
Subjects:	Nonalcoholic fatty liver disease Liver fibrosis Type 2 diabetes mellitus Acute myocardial infarction Noninvasive biomarkers
Online Access:	https://doi.org/10.1186/s12933-023-02024-x

Similar Items

The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease
by: A. S. Kuznetsova, et al.
Published: (2023-01-01)

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
by: Jung Hwan Yu, et al.
Published: (2023-02-01)

Potential Hepatic Lipid Markers Associated with Nonalcoholic Steatohepatitis and Fibrosis in Morbid Obesity Patients
by: Hua-Chien Wu, et al.
Published: (2023-05-01)

The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan
by: Yuya Seko, et al.
Published: (2020-10-01)

Development and validation of an online dynamic nomogram based on the atherogenic index of plasma to screen nonalcoholic fatty liver disease
by: Hewei Peng, et al.
Published: (2023-03-01)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
by: Chanbin Lee, et al.
Published: (2019-10-01)

Noninvasive assessment of nonalcoholic fatty liver disease
by: Gajanan A Rodge, et al.
Published: (2021-01-01)

A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease
by: Ahmad Hassan Ali, et al.
Published: (2021-07-01)

Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
by: Reeju Amatya, et al.
Published: (2023-07-01)

The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
by: Ivana Mikolasevic, et al.
Published: (2022-02-01)

Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies
by: Dhaval Gosalia, et al.
Published: (2022-10-01)

Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder
by: Kenzaburo Yamaji, et al.
Published: (2023-10-01)

Sex hormone binding globulin (SHBG) as a predictor of liver fibrosis in subjects with nonalcoholic fatty liver disease (NAFLD)
by: Abeer Abdel-latif, et al.
Published: (2023-05-01)

Association of Dietary Acid Load with Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in US Adults: Evidence from NHANES 1999–2018
by: Cheng J, et al.
Published: (2023-12-01)

Fibrosis-3 Index: A New Score to Predict Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Without Age as a Factor
by: Kazuya Kariyama, et al.
Published: (2022-01-01)

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
by: Georgiana-Emmanuela Gîlcă-Blanariu, et al.
Published: (2023-10-01)

Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Man-Hoon Han, et al.
Published: (2020-05-01)

Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
by: Lei Miao, et al.
Published: (2022-06-01)

Association of Non-Invasive Markers with Significant Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
by: Zhang F, et al.
Published: (2023-07-01)

Liver Disease Assessment in Children with Fontan and Glenn Surgeries for Univentricular Hearts—The Role of Elastography and Biochemical Fibrosis Markers
by: Roxana-Cristina Mareș, et al.
Published: (2022-07-01)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
by: Maria Sotiropoulou, et al.
Published: (2021-01-01)

Combining serum uric acid and fatty liver index to improve prediction quality of nonalcoholic fatty liver disease
by: Yajie Ding, et al.
Published: (2023-01-01)

Changed Amino Acids in NAFLD and Liver Fibrosis: A Large Cross-Sectional Study without Influence of Insulin Resistance
by: Takuma Hasegawa, et al.
Published: (2020-05-01)

Clinical Value of Non-Invasive Indicators in Predicting Advanced Liver Fibrosis in Children with Autoimmune Hepatitis
by: Soudabeh Hamedi-Shahraki, et al.
Published: (2023-05-01)

Severity of Liver Fibrosis Is Associated with the Japanese Diet Pattern and Skeletal Muscle Mass in Patients with Nonalcoholic Fatty Liver Disease
by: Yoshinari Matsumoto, et al.
Published: (2023-02-01)

Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
by: Clémence M. Canivet, et al.
Published: (2022-12-01)

Nonalcoholic Fatty Liver Disease and the Kidney: A Review
by: Ilaria Umbro, et al.
Published: (2021-10-01)

Dietary inflammatory index in relation to the progression of hepatic steatosis and liver fibrosis: evaluation by elastography/Fibroscan
by: Mahsa Miryan, et al.
Published: (2024-04-01)

How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
by: Flavia Vernin de Oliveira Terzi, et al.
Published: (2023-11-01)

NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study
by: Renling Yao, et al.
Published: (2024-01-01)

Periostin as a modulator of chronic cardiac remodeling after myocardial infarction
by: Marcos F. Minicucci, et al.
Published: (2013-10-01)

Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers
by: Tamara Bassal, et al.
Published: (2022-11-01)

Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
by: Lili Liu, et al.
Published: (2023-01-01)

Noninvasive Diagnosis of NAFLD and NASH
by: Valeria Annarita Piazzolla, et al.
Published: (2020-04-01)

Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
by: Man Wang, et al.
Published: (2022-10-01)

Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable?
by: Shasha Ma, et al.
Published: (2024-02-01)

Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
by: Yuanbin Liu, et al.
Published: (2023-10-01)

Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
by: Jun-Hyuk Lee, et al.
Published: (2023-12-01)

Fibrosis biomarkers and global myocardial strain in the diagnosis and prediction of diastolic dysfunction in patients with myocardial infarction and preserved ejection fraction
by: A. V. Osokina, et al.
Published: (2021-07-01)

Cardioprotective action of metformin in experimental isoproterenol-induced myocardial infarction
by: D.Ch. Aningo, et al.
Published: (2022-05-01)